급성 췌장염 시장 규모, 점유율, 성장 분석 : 진단별, 원인별, 치료별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Acute Pancreatitis Market size was valued at USD 6.14 Billion in 2024 and is poised to grow from USD 6.5 Billion in 2025 to USD 10.29 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The global acute pancreatitis market encompasses the landscape surrounding the diagnosis, treatment, and management of this severe condition characterized by sudden pancreatic inflammation. Several factors stimulate market growth, including the rising prevalence of acute pancreatitis, advancements in diagnostic methodologies, and the emergence of innovative treatment alternatives. Heightened risk factors such as obesity, alcohol use, gallstones, and certain medications further exacerbate the condition's incidence worldwide. The market is notably competitive, with numerous pharmaceutical companies, medical device manufacturers, and healthcare providers engaged in the development and commercialization of cutting-edge solutions. Key players are focusing on clinical trials, partnerships, and strategic collaborations to expand their offerings and enhance market position. This dynamic market aims to provide effective care solutions to address the complexities associated with acute pancreatitis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Pancreatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Pancreatitis Market Segments Analysis

Global Acute Pancreatitis Market is segmented by Diagnosis, Cause, Treatment, End user and region. Based on Diagnosis, the market is segmented into Imaging Tests and Laboratory Tests. Based on Cause, the market is segmented into Gallstones, Alcohol and Others. Based on Treatment, the market is segmented into Intravenous fluid, Nutritional support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is poised for significant growth due to several interrelated factors. A notable rise in diabetes cases is expected to contribute, as pancreatitis can impair insulin-producing cells in the pancreas, leading to increased diabetes risk among affected individuals. Furthermore, an aging population coupled with heightened government initiatives aimed at raising awareness about pancreatitis is likely to bolster market demand. The influence of evolving consumer lifestyles, along with supportive government policies, will also play a pivotal role in market expansion. Additionally, the rising prevalence of obesity and pancreatic cancer will further propel the market's growth trajectory.

Restraints in the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is expected to experience sluggish growth due to a range of significant challenges. High treatment costs significantly hinder accessibility, particularly in developing regions where healthcare facilities may be limited. Furthermore, a stringent regulatory landscape complicates the introduction of new therapies and technologies, creating additional barriers to market expansion. Additionally, inadequate reimbursement practices and a general lack of public awareness about the condition further contribute to the constraints faced by the industry. Together, these factors are likely to impede the market's development and limit opportunities for growth in the treatment of acute pancreatitis.

Market Trends of the Global Acute Pancreatitis Market

The global acute pancreatitis market is witnessing transformative trends that focus on enhancing patient outcomes through various innovative strategies. A significant shift towards early diagnosis and intervention is emerging, with healthcare professionals emphasizing advanced diagnostic tools to facilitate timely treatment initiation. Additionally, the rise of personalized medicine is reshaping the therapeutic landscape, driven by genetic insights and molecular diagnostics that cater to individual patient profiles. This trend is fostering the development of targeted therapies designed to address the unique variations in acute pancreatitis. Complementing these approaches, there is an increasing integration of digital health solutions and minimally invasive interventions, collectively aiming to streamline patient management and improve recovery rates. Overall, these market trends reflect a commitment to advancing the quality of care in acute pancreatitis treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Acute Pancreatitis Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging Tests
• Laboratory Tests

Global Acute Pancreatitis Market Size by Cause & CAGR (2026-2033)

• Market Overview
• Gallstones
• Alcohol
• Others

Global Acute Pancreatitis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Intravenous fluid
• Nutritional support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Others

Global Acute Pancreatitis Market Size by End user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Acute Pancreatitis Market Size & CAGR (2026-2033)

• North America (Diagnosis, Cause, Treatment, End user)
  • US
  • Canada
• Europe (Diagnosis, Cause, Treatment, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Cause, Treatment, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Cause, Treatment, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Cause, Treatment, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCM Lifescience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GNT Pharma Co. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• General Electric Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations